Everyday Health on MSN
Exercise and mild cognitive impairment (MCI): Strengthen your body, relax your mind
Discover the cognitive benefits of exercise for those with mild cognitive impairment. Learn how aerobic, strength, and flexibility training reduce stress and boost brain health.
A trial found six weeks of yoga improved sleep quality and reduced fatigue in people with MS, suggesting its use as a ...
One of the biggest trends this year - fitness programs for older adults. With the baby boomer generation including 73 million ...
In the fast-paced ecosystem of Silicon Valley, "data" isn’t just a buzzword—it’s the currency of innovation. But realizing you need a data-focused master’s degree is only the first step. The harder ...
High-intensity interval training, or HIIT, is a great way to get in a fast, effective workout. This quick routine is helpful ...
Paralyzed Veterans of America has launched a free, online, adaptive fitness and wellness program for vets with MS, ALS, and spinal injuries.
Apple today announced a number of updates to Apple Fitness+ and activity with the Apple Watch. Apple added that many people abandon New Year's fitness resolutions by the second Friday of January, ...
We lead busy lives, and between school, work or spending time with family, it can be tricky to make time for working out, especially when first establishing a regular exercise routine. But keep this ...
– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – “At Gilead, we develop novel antiviral ...
FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its ...
Women's Health may earn commission from the links on this page, but we only feature products we believe in. Why Trust Us? My name is Cori Ritchey, and I am an exercise physiology nerd turned fitness ...
Contineum Therapeutics, Inc. (NASDAQ: CTNM) on Thursday shared topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist for relapsing-remitting multiple sclerosis (RRMS). RRMS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results